Shares of FibroGen Inc. (NASDAQ:FGEN) rose 1.8% during trading on Friday . The stock traded as high as $18.94 and last traded at $18.78, with a volume of 112,137 shares. The stock had previously closed at $18.45.

FGEN has been the topic of several research analyst reports. Zacks Investment Research cut FibroGen from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Credit Suisse Group AG reaffirmed a “buy” rating and set a $38.00 price target on shares of FibroGen in a research note on Tuesday, May 10th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $33.25.

The stock’s 50-day moving average is $17.81 and its 200 day moving average is $18.33. The stock’s market cap is $1.20 billion.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.36 by $0.01. On average, equities research analysts forecast that FibroGen Inc. will post ($1.24) EPS for the current fiscal year.

In other FibroGen news, CEO Thomas B. Neff sold 27,000 shares of FibroGen stock in a transaction on Friday, May 20th. The stock was sold at an average price of $17.68, for a total value of $477,360.00. Following the completion of the transaction, the chief executive officer now directly owns 3,526,053 shares of the company’s stock, valued at approximately $62,340,617.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas B. Neff sold 37,798 shares of FibroGen stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $18.38, for a total value of $694,727.24. Following the completion of the transaction, the chief executive officer now directly owns 3,413,255 shares of the company’s stock, valued at $62,735,626.90. The disclosure for this sale can be found here.

Other institutional investors recently made changes to their positions in the company. California Public Employees Retirement System bought a new position in shares of FibroGen during the fourth quarter valued at $3,397,000. Cornerstone Capital Management Holdings LLC. bought a new position in shares of FibroGen during the fourth quarter valued at $3,067,000. Rhumbline Advisers boosted its position in shares of FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock valued at $1,400,000 after buying an additional 3,675 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock valued at $1,932,000 after buying an additional 1,100 shares in the last quarter.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.